ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:
- June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
- June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)
Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.
ORIC Pharmaceuticals has filed a 424B3 prospectus for the resale of up to 19,230,845 shares of common stock by selling stockholders. This includes 14,130,313 outstanding shares and 5,100,532 shares issuable upon exercise of pre-funded warrants from a May 2025 private placement that raised approximately $125 million at $6.50 per share.
The company is advancing two key clinical-stage candidates:
- ORIC-944: A PRC2 inhibitor for prostate cancer, showing promising Phase 1b results. Currently in combination trials with apalutamide and darolutamide. Phase 3 trial planned for H1 2026.
- ORIC-114: A brain-penetrant EGFR/HER2 inhibitor for solid tumors, demonstrating both systemic and intracranial activity. Phase 1b trials ongoing with data updates expected in H2 2025 and Phase 3 trials planned for 2026.
As an emerging growth company, ORIC focuses on developing therapies targeting cancer resistance mechanisms in hormone-dependent cancers, precision oncology, and tumor dependencies.
Insider Trading Alert: Angie You, Director at Oric Pharmaceuticals (ORIC), has made significant stock purchases over two consecutive days in June 2025:
- June 20, 2025: Acquired 26,597 shares at weighted average price of $9.3871 per share
- June 23, 2025: Purchased additional 1,403 shares at $9.43 per share
Total position following these transactions: 28,000 shares held directly. The first purchase was executed across multiple price points ranging from $9.14 to $9.50. These direct market purchases by a director signal potential confidence in the company's prospects. The transactions were reported via Form 4 filing and executed through an attorney-in-fact, Christian Kuhlen.
The SEC has declared Oric Pharmaceuticals' Form S-3 registration statement effective as of June 20, 2025, at 4:00 P.M. The registration statement was filed under file number 333-287949.
Form S-3 is a shelf registration that allows publicly traded companies to register securities for future public offerings. This effectiveness notice indicates that Oric Pharmaceuticals has met SEC requirements and can now proceed with their planned securities offering(s).
This regulatory development suggests that Oric Pharmaceuticals may be positioning itself for potential future capital raising activities, which could include offerings of common stock, preferred stock, debt securities, warrants, or other securities as specified in their registration statement.